Aptorum Group Limited logo
Aptorum Group Limited APM
report update icon

Annual report 2026
added 05-14-2026

Aptorum Group Limited Balance Sheet 2026-2011 | APM

Brief overview of Aptorum Group Limited's balance sheet strength

The balance sheet is assessed across five available annual reports spanning 2021 to 2025.

Assets finished at $18.7 million versus $21.9 million initially, losing -14.7%. The balance sheet contracted.

Liability growth of +11.3% exceeded asset growth of -14.7%, increasing reliance on outside funding.

Internal capital represents 123.7% of the balance sheet, previously 79.9%. This is a strong capital position.

The balance sheet includes a negative accumulated result of -$73.8 million. It should be assessed alongside historical profits and capital distributions.

Overall assessment

Aptorum Group Limited's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.

Annual Balance Sheet Aptorum Group Limited

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - -758 K 1.18 M -1.44 M - -2.77 M -4.89 M -1.71 M -15.8 M - - - - - -

Long Term Debt

- - 14.2 K 3.06 M 130 K 296 K 296 K 295 K 3.42 M - - - - - - -

Long Term Debt Current

- 24.4 K 102 K 125 K 311 K - 433 K - - - - - - - - -

Total Non Current Liabilities

- - - - - - 2.21 M 6.43 M 144 K - - - - - - -

Total Current Liabilities

- 4.59 M 4.34 M 2.1 M 12.5 M 4.38 M 3.87 M 2.67 M 12.2 M - - - - - - -

Total Liabilities

- 4.9 M 4.35 M 5.26 M 13 M 4.4 M 6.08 M 9.1 M 12.3 M 1.33 M - - - - - -

Retained Earnings

- -73.8 M -72.4 M -68.2 M -65.3 M -55.5 M -30.5 M -37.6 M -17.4 M -2.55 M - - - - - -

Total Assets

- 18.7 M 16.1 M 20.6 M 20.9 M 21.9 M 44.2 M 24 M 45.1 M 31.6 M - - - - - -

Cash and Cash Equivalents

- 3.45 M 874 K 2.01 M 1.88 M - 3.5 M 5.19 M 12 M 30 K 302 K - - - - -

Book Value

- 13.8 M 11.8 M 15.4 M 7.83 M 17.5 M 38.2 M 14.9 M 32.7 M 30.2 M - - - - - -

Total Shareholders Equity

- 23.1 M 21.1 M 24.8 M 15.7 M 17.5 M 41.8 M 14.9 M 33.1 M 30.2 M - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Aptorum Group Limited

2025-Q4 2025-Q3 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- 14.2 K 3.33 M 14.2 K 62.7 K 3.06 M 199 K - - - - 296 K - 296 K - 296 K - 336 K - 295 K - - - 3.42 M - - - 1.76 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

4.9 M 4.42 M 4.34 M 4.35 M 4.53 M 5.26 M 1.63 M - - - - 4.4 M - 5.24 M - 6.08 M - 5.79 M - 9.1 M - - - 12.3 M - - - 1.33 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-73.8 M -73.5 M -72.9 M -72.4 M -70.8 M -68.2 M -70.8 M - - - - -55.5 M - -46.6 M - -30.5 M - -43.8 M - -37.6 M - - - -17.4 M - - - -2.55 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

18.7 M 17.6 M 18.1 M 16.1 M 17.7 M 20.6 M 14.4 M - - - - 21.9 M - 31.7 M - 44.2 M - 23.3 M - 24 M - - - 45.1 M - - - 31.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

3.45 M 2.27 M 2.76 M 874 K 783 K 2.01 M 340 K - - - - 8.13 M - 19.9 M - 3.5 M - 4.02 M - 5.19 M - 4.47 M - 12 M - - - 16.2 M - - 30 K 302 K - - - - - - - - - - - - - - - - - - - - - - -

Book Value

13.8 M 13.2 M 13.8 M 11.8 M 13.2 M 15.4 M 12.8 M - - - - 17.5 M - 26.5 M - 38.2 M - 17.5 M - 14.9 M - - - 32.7 M - - - 30.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

23.1 M 22.5 M 23.1 M 21.1 M 22.7 M 24.8 M 21.8 M - - - - 23.6 M - 31.5 M - 41.8 M - 19.8 M - 16.4 M - 24 M - 33.1 M - - - 30.2 M - - 24.5 M - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Aptorum Group Limited, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Revolution Medicines Revolution Medicines
RVMD
$ 207.32 0.24 % $ 39.4 B usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 101.8 0.08 % $ 6.62 B usaUSA
Rezolute Rezolute
RZLT
$ 4.4 0.88 % $ 334 M usaUSA
Sana Biotechnology Sana Biotechnology
SANA
$ 3.45 0.77 % $ 874 M usaUSA
Seer Seer
SEER
$ 1.95 0.26 % $ 108 M usaUSA
Precigen Precigen
PGEN
$ 6.87 0.14 % $ 2.15 B usaUSA
SIGA Technologies SIGA Technologies
SIGA
$ 3.2 1.86 % $ 229 M usaUSA
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
$ 19.94 0.05 % $ 1.73 B usaUSA
Soligenix Soligenix
SNGX
$ 0.38 1.18 % $ 1.97 M usaUSA
Spruce Biosciences Spruce Biosciences
SPRB
$ 59.09 2.0 % $ 45.3 M usaUSA
Sarepta Therapeutics Sarepta Therapeutics
SRPT
$ 20.94 0.04 % $ 2.1 B usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
$ 30.05 0.81 % $ 1.78 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
$ 19.1 0.34 % $ 162 M usaUSA
Shattuck Labs Shattuck Labs
STTK
$ 6.5 0.29 % $ 452 M usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 42.43 0.23 % $ 2.4 B usaUSA
Savara Savara
SVRA
$ 5.53 2.98 % $ 1.23 B usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.24 0.45 % $ 1.52 M chinaChina
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 18.32 1.49 % $ 28.9 B japanJapan
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 72.31 0.01 % $ 11.3 B usaUSA
Tenax Therapeutics Tenax Therapeutics
TENX
$ 1.98 2.06 % $ 77.7 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 36.76 1.21 % $ 42.1 B israelIsrael
TG Therapeutics TG Therapeutics
TGTX
$ 55.74 0.58 % $ 8.04 B usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 16.82 1.17 % $ 2.27 B usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 5.48 0.54 % $ 1.75 B usaUSA
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 69.37 0.35 % $ 193 M israelIsrael
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
$ 43.82 0.02 % $ 2.11 B israelIsrael
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 497.97 2.12 % $ 22.1 B usaUSA
Spero Therapeutics Spero Therapeutics
SPRO
$ 1.19 0.41 % $ 66.7 M usaUSA
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 57.42 3.78 % $ 6.59 B usaUSA
Jounce Therapeutics Jounce Therapeutics
JNCE
- - $ 98.4 M usaUSA
NextCure NextCure
NXTC
$ 8.42 7.67 % $ 23.9 M usaUSA
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
$ 5.26 0.75 % $ 56 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 23.17 1.09 % $ 2.36 B usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
- 7.23 % $ 2.72 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 528.9 0.22 % $ 135 B usaUSA
Verastem Verastem
VSTM
$ 8.08 0.55 % $ 560 M usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
$ 32.79 0.03 % $ 130 M usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
$ 3.4 3.85 % $ 200 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
$ 4.91 1.03 % $ 828 M singaporeSingapore
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 13.16 0.15 % $ 112 M usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 4.28 0.86 % $ 7.28 M usaUSA
XBiotech XBiotech
XBIT
$ 2.18 0.23 % $ 66.5 M usaUSA
Exicure Exicure
XCUR
$ 1.41 12.8 % $ 8.88 M usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 59.55 0.18 % $ 4.72 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
$ 8.48 0.12 % $ 1.36 B usaUSA